Technical Analysis for IMM - Immupharma Plc

Grade Last Price % Change Price Change
F 5.42 8.40% 0.42
IMM closed down 7.41 percent on Thursday, December 2, 2021, on 2.32 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical IMM trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 8.40%
Lower Bollinger Band Walk Weakness 8.40%
New 52 Week Low Weakness 8.40%
Stochastic Reached Oversold Weakness 8.40%
Wide Bands Range Expansion 8.40%
Below Lower BB Weakness 8.40%
Lower Bollinger Band Touch Weakness 8.40%
Oversold Stochastic Weakness 8.40%
Jack-in-the-Box Bearish Bearish Swing Setup 0.37%
Lower Bollinger Band Walk Weakness 0.37%
Older End-of-Day Signals for IMM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible Inside Day about 5 hours ago
5x Volume Pace about 9 hours ago
3x Volume Pace about 9 hours ago
2x Volume Pace about 9 hours ago
1.5x Volume Pace about 9 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Immupharma Plc Description

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.


Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Medicine Clinic Cement Disease Earl Cancer Medical Specialties Diseases Drugs Mr Drug Discovery Autoimmune Diseases Disorders Infection Antibiotic Infectious Diseases Patent Infections Lupus Antibiotics Bacterial Diseases Healthcare Associated Infections Methicillin Opioids Staphylococcus Aureus

Is IMM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 14.05
52 Week Low 4.8628
Average Volume 558,550
200-Day Moving Average 8.22
50-Day Moving Average 7.02
20-Day Moving Average 6.64
10-Day Moving Average 6.24
Average True Range 0.71
ADX 24.11
+DI 9.88
-DI 20.58
Chandelier Exit (Long, 3 ATRs) 5.36
Chandelier Exit (Short, 3 ATRs) 7.01
Upper Bollinger Bands 7.93
Lower Bollinger Band 5.36
Percent B (%b) -0.14
BandWidth 38.63
MACD Line -0.42
MACD Signal Line -0.24
MACD Histogram -0.1787
Fundamentals Value
Market Cap 12.51 Million
Num Shares 250 Million
EPS -5.10
Price-to-Earnings (P/E) Ratio -0.98
Price-to-Sales 168.34
Price-to-Book 5.29
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.41
Resistance 3 (R3) 6.52 6.16 6.17
Resistance 2 (R2) 6.16 5.80 6.10 6.09
Resistance 1 (R1) 5.58 5.58 5.40 5.47 6.02
Pivot Point 5.22 5.22 5.13 5.17 5.22
Support 1 (S1) 4.64 4.86 4.46 4.53 3.98
Support 2 (S2) 4.28 4.64 4.23 3.91
Support 3 (S3) 3.70 4.28 3.83
Support 4 (S4) 3.59